95034-05-2

Basic information

• Product Name: (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL 2-AMINO-2-METHYLPROPYLCARBAMATE;Tert-butyl N-(2-amino-2-methylpropyl)carbamate
• CAS NO: 95034-05-2
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Mol File: 95034-05-2.mol

Chemical Properties

• Boiling Point: 275.1±23.0 °C(Predicted)
• Appearance: /
• Density: 0.974±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 13.42±0.46(Predicted)
• CAS DataBase Reference: (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER(95034-05-2)
• EPA Substance Registry System: (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER(95034-05-2)

Safety Data

• Hazardous Substances Data: 95034-05-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the formation of complex organic molecules.
Used in Peptide and Protein Chemistry:
In the field of peptide and protein chemistry, (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER serves as a protecting group for amines. This function is crucial for preventing unwanted side reactions during the synthesis of peptides and proteins, ensuring the desired product is obtained.
Used in Pharmaceutical and Agrochemical Industries:
(2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER is utilized in the synthesis of a variety of pharmaceuticals and agrochemicals. Its role in these industries is pivotal for the development of new drugs and pesticides, enhancing the range of treatments and protections available.
Used in Polymer and Resin Manufacturing:
In the manufacturing of polymers and resins, (2-AMINO-2-METHYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER is employed to create specific polymeric materials with tailored properties. Its use in this industry contributes to the advancement of materials science and the development of new applications for polymers and resins.

Upstream product

• 13139-12-3 tert-butyl 2,5-dioxopyrrolidin-1-yl carbonate 
• 811-93-8 1,1-dimethylethylenediamine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 6627-89-0 tert-butyl phenyl carbonate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 739365-95-8 tert-butyl N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]carbamate 
• 1301177-99-0 C₃₀H₄₁BrN₄O₃ 
• 1160838-96-9 Z-Gly-Dadme-Boc 
• 1160838-90-3 C₂₂H₃₃N₃O₅ 
• 1144524-58-2 methyl 3-({[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1,1-dimethylethyl]amino}methyl)-1-phenyl-1H-indole-5-carboxylate 
• 721966-72-9 (tert-butoxy)-N-(2-{[3-(2-cyanophenoxy)-2-hydroxypropyl]amino}-2-methylpropyl) carboxamide 
• 158221-95-5 [2-({(S)-1-[(2S,3S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyryl]-pyrrolidine-2-carbonyl}-amino)-2-methyl-propyl]-carbamic acid tert-butyl ester 
• 207444-85-7 {(1S,2S)-1-Benzyl-3-[(S)-2-(2-tert-butoxycarbonylamino-1,1-dimethyl-ethylcarbamoyl)-pyrrolidin-1-yl]-2-hydroxy-3-oxo-propyl}-carbamic acid benzyl ester 

Relevant articles and documents

Gem-dimethyl peptide nucleic acid (α/β/γ-gdm-PNA) monomers: synthesis and the role ofgdm-substituents in preferential stabilisation ofZ/E-rotamers

The flexible backbone of aminoethylglycine (aeg) PNA upon substitution becomes sterically constrained to enable conformational pre-organization for preferential binding to DNA or RNA. The bulkygem-dimethyl (gdm) substituent on carbons adjacent to thet-amide sidechain either at Cα (glycyl) or Cβ/Cγ (aminoethylene) sides may influence theZ/Erotamer ratio arising from a restricted rotation around thet-amide bond. Employing 2D NMR (NOESY), it is shown here that the Cα-gdm-PNA-T monomer exhibits exclusively theZ-rotamer, while the Cβ-gdm-PNA-T monomer shows only theE-rotamer. The unsubstitutedaeg-PNA-T and Cγ-gdm-PNA-T monomers display a mixture ofZ/Erotamers. The rotamers witht-amide carbonyl pointing towards thegem-dimethyl group always prevailed. The results are supported by computational studies that suggested that the preferred rotamers are the outcome of a net energetic benefit from the stabilising n-π* interactions of carbonyls (amide backbone andt-amide sidechain), and C-H?O interactions and the destabilising steric clash ofgem-dimethyl groups with the t-amido methylene group. TheE-rotamer structure in Cγ-gdmis also characterised by X-ray crystallography. The exclusiveE-rotamer for the Cβ-gdmmonomer seen in solution here is the first such example among several modified PNA monomers. Since the conformation of the sidechain is important for inducing base stacking and effective base pairing, the exclusiveE-rotamer in the Cβ-gdmmonomer may have significance in the properties of the derived PNA?:?DNA/RNA duplexes with allE-rotamers.

ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS

Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS

The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.

AN ADVANTAGEOUS PROCESS FOR PREPARING ANAGLIPTIN AND ITS NOVEL CRYSTALLINE FORM-H

The present invention discloses the process for preparation of Anagliptin and its novel crystalline form-H.

TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY

This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

A PROCESS FOR THE PREPARATION OF ANAGLIPTIN AND ITS INTERMEDIATES THEREOF

The present invention relates to an improved process for the preparation of Anagliptin, intermediates thereof, or pharmaceutically acceptable thereof. The present invention also direct to another short process for the preparation of Anagliptin. The present invention also specifically provides an improved process for the purification of intermediate of Anagliptin. Further, the present invention relates to a polymorph of Anagliptin or a pharmaceutically acceptable salt thereof and a method for the preparation thereof.

Influence of achiral units with gem-dimethyl substituents on the helical character of aliphatic oligourea foldamers

The structures of various urea oligomers incorporating one or two central achiral 1,2-diamino-1,1-dimethylethane (DADME) units have been investigated in solution and in the crystalline state. These diamine monomers are analogous to the achiral helicogenic

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.